Destiny Pharma plc Financials

Market Capitalization £8.1 Million as of July 1, 2024

Valuations Metrics as of May. 5, 2024

Trailing PE	-196.29
Forward PE	-2.15
Price to Sales TTM	£20.92
Price to Book MRQ	£190.10
Enterprise to Revenue	13.23
Enterprise to EBITDA	-1.64

Financial Reports as of Jun. 30, 2023

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2023-06-30
Profit Margin	0.00%
Operating Margin	-810.05%
Return on Assets TTM	-44.90%
Return on Equity TTM	-67.29%

Income Statement

Revenue TTM	£831,552
Revenue per Share TTM	£0.01
Quarterly Revenue Growth	-100.00%
Gross Profit TTM	£0
EBITDA	£-6,729,798
Net Income to Common TTM	£-5,657,036
Diluted EPS TTM	£-0.06
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	£6,382,603
Total Cash per Share MRQ	£0.07
Total Debt MRQ	£
Total Debt to Equity MRQ	0.00
Current Ratio MRQ	9.89
Book Value per Share MRQ	£0.10

Cash Flow

Operating Cash Flow TTM	£-5,474,474
Levered Free Cash Flow TTM	£-3,818,522

DEST Stock Info as of May. 5, 2024

Stock Statistics

Shares Outstanding	95,311,904
Float Shares	74,708,384
Avg 10 Volume	1,291,041
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	24.65%
% Held by Institutions	27.33%

Stock Price Summary

Beta	0.24
Fifty Two Week Low	£13.20
Fifty Two Week High	£84.00
Fifty Two Week Change	-89.59%
Day 50 MA	£26.54
Day 200 MA	£50.88

Dividends and Splits

Forward Annual Dividend Rate	£
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	£0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date